![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Extends Shelf Life of Four Lots of Paxlovid to 12 Months
FDA Extends Shelf Life of Four Lots of Paxlovid to 12 Months
July 28, 2022
The FDA has extended the shelf life of four lots of Pfizer’s COVID-19 drug Paxlovid (nirmatrelvir, ritonavir) from nine months to 12 months.
The extension affects lots with expiration dates either on July 31 or August 31 that were labeled with a nine-month shelf life before the drug received Emergency Use Authorization (EUA) from the agency. The December 2021 EUA established a 12-month shelf life for all Paxlovid lots.
The EUA for Paxlovid is for treatment of mild-to-moderate COVID-19 adult and pediatric patients 12 years and older who weigh at least 88 pounds.
Upcoming Events
-
21Oct